Cutler Group LP Allogene Therapeutics, Inc. Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$10.32 - $17.28 $17,956 - $30,067	-1,740 Reduced 56.13%	1,360 $14,000
Q2 2022 Aug 04, 2022	SELL	$6.78 - $12.28 $21,302 - $38,583	-3,142 Reduced 50.34%	3,100 $35,000
Q1 2022 Apr 14, 2022	BUY	$7.65 - $15.29 $9,945 - $19,877	1,300 Added 26.31%	6,242 $56,000
Q4 2021 Jan 18, 2022	BUY	$13.13 - $24.52 $42,567 - $79,493	3,242 Added 190.71%	4,942 $73,000
Q3 2021 Oct 26, 2021	SELL	$21.01 - $27.64 $4,202 - $5,528	-200 Reduced 10.53%	1,700 $43,000
Q2 2021 Jul 19, 2021	BUY	$23.49 - $35.8 $35,235 - $53,699	1,500 Added 375.0%	1,900 $49,000
Q1 2021 Apr 26, 2021	BUY	$25.79 - $39.02 $10,316 - $15,608	400 New	400 $14,000
Q4 2020 Jan 21, 2021	SELL	$25.24 - $43.45 $2,524 - $4,345	-100 Closed	0 $0
Q3 2020 Oct 27, 2020	SELL	$32.38 - $44.96 $16,190 - $22,480	-500 Reduced 83.33%	100 $3,000
Q3 2019 Oct 28, 2019	BUY	$26.11 - $32.99 $15,666 - $19,794	600 New	600 $16,000

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $233M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.